Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for
treating aplastic anemia and some other forms of bone marrow failure.
Researchers are currently studying MMF in combination with other medicines for
treating aplastic anemia.
It is still an investigational therapy, in combination with other medications, for
treating aplastic anemia and other forms of bone marrow failure.
Alemtuzumab is in clinical trials for
treating aplastic anemia.
Doctors generally
treat aplastic anemia effectively using immunosuppressives — drugs that prevent the immune system from attacking bone marrow — allowing recovery of the patient's own marrow and long - term survival.
Not exact matches
If so, says Grover Bagby, a hematologist who directs the Oregon Cancer Center at the Oregon Health Sciences University in Portland, further work to decipher the protein's exact function could shed light on how to
treat a much larger population of patients with leukemia, certain other forms of cancer, and
aplastic anemia.
«In the group that was not
treated with the gene therapy, the majority of the animals die from
aplastic anemia, and they also die much sooner.»
ATG is approved by the U.S. Food and Drug Administration (FDA) for
treating moderate and severe
aplastic anemia.
«In the group that was not
treated with the gene therapy, the majority of the animals die from
aplastic anaemia, and they also die much sooner.»
Treated dogs are susceptible to bone marrow suppression from estrogen, typified by early thrombocytopenia and potentially fatal
aplastic anemia.